JT
TRVI icon

Jupiter Topco’s Trevi Therapeutics TRVI Stock Holding History

Jupiter Topco’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2M Buy
+1,190,973
New +$17.3M 0.01% 633

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jupiter Topco's TRVI Position: Q2 2026 in Review

Jupiter Topco opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 1,190,973 shares worth $22.2M. The stake represents 0.01% of the portfolio and ranks #633 among its holdings.

197 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Jupiter Topco held 1,190,973 shares of Trevi Therapeutics worth $22.2M as of Q2 2026.
  • Trevi Therapeutics was a new Jupiter Topco position in Q2 2026.
  • Trevi Therapeutics made up 0.01% of Jupiter Topco's portfolio in Q2 2026, its #633 holding.
  • 197 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.